Y-mAbs Appoints Oncology Executive Mary Tagliaferri, M.D. to its Board of Directors
to the Company’s Board of Directors, effective February 29, 2024.
- to the Company’s Board of Directors, effective February 29, 2024.
- Dr. Tagliaferri brings nearly 30 years of biopharmaceutical industry experience and oncology therapeutic development expertise to the Y-mAbs Board of Directors.
- “We are thrilled to welcome Mary to our Board of Directors during such an exciting time for Y-mAbs,” said Michael Rossi, President and Chief Executive Officer.
- Nektar is a clinical-stage, research-based drug discovery biopharmaceutical company focuses on discovering and developing innovative medicines in the field of immunotherapy.